Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 11/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 11/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14486846 | 0.83 | TAS1R3 (0.57) | TAS1R3TAS1R1MAPK1ALDH1A1PPARA | |
| SCHEMBL5782191 | 0.80 | CA2 (0.45) | ALDH1A1LMNAKDM4EKMT2APOLB | |
| SCHEMBL5784048 | 0.79 | RAB9A (0.51) | ALDH1A1PPARAKDM4EKMT2AMEN1 | |
| SCHEMBL2146379 | 0.79 | TAS1R3 (0.60) | TAS1R3TAS1R1MAPK1ALDH1A1KDM4E | |
| SCHEMBL5784579 | 0.79 | HDAC1 (0.47) | TAS1R3TAS1R1ALDH1A1LMNA | |
| SCHEMBL1828343 | 0.78 | TAS1R3 (0.52) | TAS1R3TAS1R1ALDH1A1KDM4EKMT2A | |
| SCHEMBL5784866 | 0.76 | ALDH1A1 (0.51) | ALDH1A1LMNAKMT2A | |
| SCHEMBL5784288 | 0.75 | GRN (0.44) | — | |
| SCHEMBL1829685 | 0.75 | LMNA (0.54) | ALDH1A1LMNAKDM4EKMT2APOLB | |
| SCHEMBL5782820 | 0.75 | HDAC1 (0.46) | LMNAKDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748436-B2 | Carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-20130079357-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079357-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | DPYD, OXGR1, ALDH1A1 | TAS1R3 2462/4885TAS1R1 1841/4885MAPK1 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.